BUDAPEST, Hungary and TOKYO, August 21, 2013 /PRNewswire/ --
ChemAxon, a leader in providing chemistry software solutions and consulting services for life science research, and Patcore, a leading cheminformatics software and service company for pharmaceutical and life science industries, have agreed terms for the distribution of Patcore's CRAIS series of products globally excluding Japan.
Patcore's CRAIS product series are a set of innovative cheminformatics applications covering many common processes in life science research, including: compound registration, assay management, data browsing, collaborative interfaces, structure design and controlled substance compliance.
The CRAIS products are based on ChemAxon's cheminformatics toolkits and offer users an "off the shelf" solution for common RnD processes, especially where high performance and integration within larger systems are essential.
ChemAxon is a leader in providing cheminformatics software platforms and desktop applications for the biotechnology, pharmaceutical and agrochemical industries. With core capabilities for structure visualization, search and management, property prediction, virtual synthesis, screening and drug design, ChemAxon focuses upon active interaction with users and software portability to create powerful, cost effective cross platform solutions that power modern cheminformatics and chemical communication. The company is privately owned with European headquarters in Budapest, US East Coast headquarters in Cambridge, MA, and sales and support offices in Europe, Japan and across North America.
About Patcore Inc.
Patcore is based in TOKYO, providing cheminformatics software and services for Pharmaceutical and life science industries. Patcore was founded in 2003 and signed with ChemAxon in 2005 as an exclusive partner in Japan. Patcore successfully developed CRAIS series using ChemAxon technologies to help users to manage chemical and biological data more efficiently. These products are well accepted by many clients and Patcore has provided them for 15 of the top 20 pharmaceutical companies in Japan to date.
Copyright©2012 PR Newswire.
All rights reserved